# Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

> **NCT01171976** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 373 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01171976
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171976, "Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01171976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*